Giraldoid A exhibits significant potential in pharmaceutical applications, particularly in the development of anti-inflammatory and neuroprotective agents. It has demonstrated the ability to modulate key signaling pathways involved in oxidative stress and neuronal damage, making it a candidate of interest for research into neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. Additionally, studies suggest it may enhance cellular defense mechanisms by upregulating antioxidant enzymes. Its natural origin and observed low cytotoxicity further support its evaluation in therapeutic formulations. Current research focuses on optimizing delivery methods and assessing bioavailability for future preclinical development.